COVID-19 has been a relentless challenge for over a year and a half now. Almost every country has faced periods of rising cases. The second wave spread so rapidly in some places that it felt impossible to regain control. Given the inadequate preparation for that wave, health experts and authorities are now alerting the public about the possibility of a third wave. While we can't predict exactly when or how severe it will be, many believe it's unavoidable. However, there's good news! With strong measures and proper guidelines, we can potentially lessen its impact. Here's some essential information to help you navigate the upcoming challenges.
1) Severity of The Third Wave
The second wave was nothing short of devastating. It progressed rapidly, and studies revealed that the Delta variant spread quickly, easily attaching to lung receptors, which significantly increased transmissibility and severity of illness. Research has shown that variants like Delta exhibit resistance to certain monoclonal antibody therapies, which complicates treatment options for infected individuals [2]. Experts are concerned that if vaccine coverage or prior exposure rates remain low, the third wave could indeed be worse than the last. To prevent a surge in COVID cases and mitigate the effects, following preventive measures — like handwashing, wearing masks, and maintaining social distance — is crucial.
2) The Third Wave May Not Affect Children More
In countries that experienced a severe second wave, like India, there was a notable increase in infections among children, who were previously considered less at risk. This led many to believe that the next wave would be particularly harmful to kids. However, it's important to note that there's no solid scientific evidence supporting this claim. Current studies indicate that even if the third wave does impact younger individuals, it is likely to manifest as a milder form of the disease, allowing for easier recovery [4].
3) Will Vaccines Be Less Effective Against the New Variants?
With new variants emerging, there are concerns about the effectiveness of current vaccines, particularly against the Delta variant and its newer counterpart, Delta plus. Research is ongoing to determine if booster doses or additional vaccine shots may be necessary to enhance immunity against these variants [3]. Studies have shown that anti-spike monoclonal antibodies have proven invaluable in preventing severe outcomes from COVID-19, including hospitalization and death, particularly in high-risk groups [1]. Ultimately, if we can reduce transmission through responsible behavior and increase vaccination rates, we can significantly diminish the risks that any future wave may present. Staying vigilant and adhering to safe practices will help lower virus circulation and reduce the chances of mutations that could lead to new variants.
If you're looking for guidance or have questions about COVID-19, consider using an online doctor consultation service. With the ability to talk to a doctor online, you can get the information you need from an AI doctor or chat doctor, making it easier to stay informed and safe during these uncertain times.
References:
- Atul Kothari, Elizabeth Woodland Borella, Michelle R Smith. Monoclonal Antibody Therapy for COVID-19: A Public Health Perspective From Arkansas.. PubMed. 2022.
- John C O'Horo, Douglas W Challener, Leigh Speicher, Wendelyn Bosch, Maria Teresa Seville, Dennis M Bierle, Ravindra Ganesh, Caroline G Wilker, Richard F Arndt, Lori L Arndt, Sidna M Tulledge-Scheitel, Sara N Hanson, Raymund R Razonable. Effectiveness of Monoclonal Antibodies in Preventing Severe COVID-19 With Emergence of the Delta Variant.. PubMed. 2022.
- David T Huang, Erin K McCreary, J Ryan Bariola, Tami E Minnier, Richard J Wadas, Judith A Shovel, Debbie Albin, Oscar C Marroquin, Kevin E Kip, Kevin Collins, Mark Schmidhofer, Mary Kay Wisniewski, David A Nace, Colleen Sullivan, Meredith Axe, Russell Meyers, Alexandra Weissman, William Garrard, Octavia M Peck-Palmer, Alan Wells, Robert D Bart, Anne Yang, Lindsay R Berry, Scott Berry, Amy M Crawford, Anna McGlothlin, Tina Khadem, Kelsey Linstrum, Stephanie K Montgomery, Daniel Ricketts, Jason N Kennedy, Caroline J Pidro, Anna Nakayama, Rachel L Zapf, Paula L Kip, Ghady Haidar, Graham M Snyder, Bryan J McVerry, Donald M Yealy, Derek C Angus, Christopher W Seymour. Effectiveness of Casirivimab-Imdevimab and Sotrovimab During a SARS-CoV-2 Delta Variant Surge: A Cohort Study and Randomized Comparative Effectiveness Trial.. PubMed. 2022.
- Gaetano Cicchitto, Lorena Cardillo, Claudio de Martinis, Paola Sabatini, Rosita Marchitiello, Giovanna Abate, Adele Rovetti, Antonietta Cavallera, Camillo Apuzzo, Francesco Ferrigno, Giovanna Fusco. Effects of Casirivimab/Imdevimab Monoclonal Antibody Treatment among Vaccinated Patients Infected by SARS-CoV-2 Delta Variant.. PubMed. 2022.
- Hinpetch Daungsupawong, Viroj Wiwanitkit. Delta variant, neutralizing antibody response and maternal COVID-19 vaccination.. PubMed. 2024.